Background
Methods
Alberta Kidney Disease Network (AKDN) database
Assessment of exposure to statins
Definitions
Ascertainment of outcomes
Statistical analyses
Results
High-intensity | Medium-intensity | Low-intensity | |
---|---|---|---|
n = 60,625 | n = 58,919 | n = 8596 | |
Age, yearsa | 72.7 (68.6, 78.1) | 73.1 (69, 78.5) | 73.4 (68.9, 78.8) |
Female | 45 | 53 | 55 |
Hypertension | 73 | 71 | 70 |
Diabetes | 27 | 29 | 27 |
Statin | |||
Rosuvastatin | ≥10 mg: 44 | < 10 mg: 19 | 0 |
Atorvastatin | ≥20 mg: 55 | < 20 mg: 62 | 0 |
Simvastatin | ≥80 mg: 0.3 | 20–40 mg: 20 | < 20 mg: 40 |
Lovastatin | 0 | 40 mg: 0.2 | < 40 mg: 4 |
Pravastatin | 0 | 0 | ≤40 mg: 52 |
Fluvastatin | 0 | 80 mg: 0.1 | ≤40 mg: 4 |
Comorbidities | |||
Alcohol misuse | 2 | 2 | 2 |
Asthma | 4 | 3 | 3 |
Atrial fibrillation | 12 | 10 | 10 |
Cancer, lymphoma | 1 | 1 | 1 |
Cancer, metastatic | 1 | 1 | 1 |
Cancer, non-metastatic | 7 | 6 | 6 |
Chronic heart failure | 14 | 11 | 12 |
Chronic kidney disease | 43 | 39 | 34 |
Chronic pain | 17 | 18 | 18 |
Chronic pulmonary disease | 21 | 19 | 18 |
Chronic viral hepatitis B | 0.02 | 0.04 | 0.05 |
Cirrhosis | 0.2 | 0.2 | 0.3 |
Dementia | 4 | 3 | 3 |
Depression | 9 | 9 | 9 |
Epilepsy | 1 | 1 | 1 |
Hypothyroidism | 14 | 14 | 14 |
Inflammatory bowel disease | 1 | 1 | 1 |
Irritable bowel syndrome | 2 | 2 | 2 |
Multiple sclerosis | 0.4 | 0.4 | 0.4 |
Myocardial infarction | 17 | 8 | 7 |
Parkinson’s disease | 1 | 1 | 2 |
Peptic ulcer disease | 1 | 1 | 1 |
Peripheral vascular disease | 3 | 3 | 2 |
Psoriasis | 1 | 1 | 1 |
Rheumatoid Arthritis | 4 | 4 | 3 |
Schizophrenia | 1 | 1 | 1 |
Severe constipation | 2 | 2 | 2 |
Stroke or TIA | 18 | 17 | 16 |
Proteinuria | |||
Not measured | 42 | 41 | 51 |
Normal | 46 | 47 | 39 |
Moderately increased | 10 | 10 | 8 |
Severely increased | 2 | 2 | 2 |
Medications | |||
ACEI/ARB | 65 | 58 | 56 |
Loop diuretics | 13 | 11 | 11 |
eGFR ml/min/1. 73m2 | |||
Not measured | 25 | 27 | 37 |
< 15 | 0.2 | 0.2 | 0.3 |
15–29 | 2 | 2 | 2 |
30–44 | 6 | 6 | 6 |
45–59 | 15 | 15 | 13 |
60–89 | 45 | 44 | 37 |
≥ 90 | 7 | 6 | 5 |
Association between statin use, statin regimen intensity, statin potency, and the risk of AKI
Unadjusted HR (95% CI) | Fully-adjusted* HR (95% CI) | |
---|---|---|
High-intensity | 1.35 (1.28, 1.43) | 1.16 (1.10, 1.23) |
Medium-intensity | 1.09 (1.03, 1.16) | 1.07 (1.01, 1.13) |
Low-intensity | 1.04 (0.93, 1.15) | 1.03 (0.93, 1.15) |
Non-use | 1 (referent) | 1 (referent) |
P for trend | < 0.001 | < 0.001 |